

patient/family preference for procedure

| Patient Name:  |  |
|----------------|--|
| Date of Birth: |  |

Page 1 of 5

PHYO Growth Hormone (Arginine / Clonidine)
CMC84728-001NS Rev. 11/2020 Stimulation Test

| CIVIC64726-001N3                    | Rev. 11/2020   | Stimulation rest                       |               |                |   |
|-------------------------------------|--|--|---------------|----------------|---|
|                                     | ENT DEMOGRAPHIC  |  |               |                |   |
| _                                   | by the ordering provide                                  |  | \             |                | Darla Confere Asses   |
|                                     | nown Drug Allergies                                      | _                                      | vveignt: _    | K              | g Body Surface Area: (m <sup>2</sup> )  |
| ☐ Allergies:                        |  |  |               |                |   |
| Treatment should                    | d begin: ☐ as soon a                                     | s possible (within a week)             | ☐ within      | n the month    |   |
| ORDERS TO BE                        | COMPLETED FOR EA   | CH THERAPY                             |               |                |   |
| ADMIT ORDERS                        | <b>3</b>   |  |               |                |   |
| ✓ Nursing compatient needs t        | munication o be fasting for test.                        |  |               |                |   |
| ☑ Height and v                      | veight   |  |               |                |   |
| ☑ Vital signs                       | _  |  |               |                |   |
| NURSING ORD                         | ERS  |  |               |                |   |
| Please select al                    | I appropriate therapy                                    |  |               |                |   |
|                                     | SING ORDERS  |  |               |                |   |
| ☐ Insert peripl                     |  | railable                               |               |                |   |
| ☐ lidocaine 1%<br>0.2 mL, intrade   | <b>6 BUFFERED (J-TIP L</b> lermal, PRN                   | DOCAINE) injection                     |               |                |   |
| when imme                           | diate procedure needed                                   |  |               |                |   |
| ☐ when proce                        | edure will take about 1 min                              | ute                                    |               |                |   |
| patient/fam                         | ily preference for procedu                               | ·e                                     |               |                |   |
|                                     |  |  |               |                | sorders, platelets ≤ 20,000, or in patients taking otherapy administration, nor for pre-term infants or |
| ☐ <b>lidocaine - p</b> Topical, PRN | rilocaine (EMLA) crea                                    | m                                      |               |                |   |
| ☐ when more                         | than 60 minutes are avai                                 | lable before procedure                 |               |                |   |
| ☐ when proc                         | edure will take more than                                | 1 hour                                 |               |                |   |
| <del>-</del> ·                      | nily preference for procedu<br>Instructions: NOTE: In ch | re<br>ildren < 3 months of age, or < 5 | 5 kg in weigł | nt, maximum ap | oplication time is 1 hour.  |
| ☐ lidocaine - to                    | etracaine (SYNERA) p                                     | atch                                   |               |                |   |
| Topical, PRN                        | , , , , ,  |  |               |                |   |
| -                                   | 30 minutes are available b                               | efore procedure                        |               |                |   |
| _                                   | edure will take more than                                |  |               |                |   |
| ☐ when antic                        | ipated pain is <b>l</b> ess than 5                       | mm from skin surface                   |               |                |   |



| Patient Name:  |  |
|----------------|--|
| Date of Birth: |  |

Page 2 of 5

PHYO Growth Hormone (Arginine / Clonidine CMC84728-001NS Rev. 11/2020 Stimulation Test

| Growtl  | h Hormone (Arginine / Clonidine) |  |
|---------|----------------------------------|--|
| 14/2020 | Stimulation Toot                 |  |

# ORDERS TO BE COMPLETED FOR EACH THERAPY

| NURSING ORDERS, CONTINUED  |
|--|
| □ lidocaine with transparent dressing 4 % kit Topical, PRN □ when 20 - 30 minutes are available before procedure □ when procedure will take more than 1 hour □ patient/family preference for procedure   |
| Select one:  |
| □ heparin 10 - 50 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. This heparin flush should be used with all central lines including IVADs, with the exception of de-accessing the IVAD. |
| ☐ heparin flush 100 - 300 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. For use only when de-accessing IVADs.  |
| Sodium chloride flush 0.9% injection 1 - 20 mL, INTRAVENOUS, PRN, IV line flush  |
| ☐ Sodium chloride - pres free 0.9% injection 1 - 30 mL, INTRAVENOUS, PRN, IV line flush  |
| PRE-PROCEDURE LABS   |
| <ul> <li>✓ Human growth hormone         Unit collect draw prior to cloNlDine dose</li> <li>✓ Cortisol total         Unit collect</li> </ul>  |
| ☐ T4 free Unit collect   |
| ☐ Thyroid stimulating hormone Unit collect   |
| Insulin like growth factor - 1 Unit collect  |
| ☐ Insulin like growth factor BP - 3 Unit collect   |
| Luteinizing hormone Unit collect   |
| ☐ Follicle stimulating hormone Unit collect  |
| ☐ Estradiol Unit collect   |
| ☐ Testosterone Unit collect  |
| ☐ Chromosome karyotype study Unit collect  |



| Patient Name:  |  |
|----------------|--|
| Date of Birth: |  |

Page 3 of 5

PHYO Growth Hormone (Arginine / Clonidine) CMC84728-001NS Rev. 11/2020 Stimulation Test

# OPDERS TO BE COMPLETED FOR EACH THERABY

| RD | ERS TO BE COMPLETED FOR EACH THERAPY   |
|----|--|
| PR | E-PROCEDURE LABS, CONTINUED  |
|    | Comprehensive metabolic panel Unit collect   |
|    | Complete blood count with differential Unit collect  |
|    | Tissue transglutaminase IgA Unit collect   |
|    | Immunoglobulin A Unit collect  |
|    | Prolactin Unit collect   |
|    | Adrenocorticotropic hormone (ACTH) Unit collect  |
| IN | TRA - PROCEDURE  |
| ☑  | Vital signs Routine, EVERY 30 MINUTES, vital signs, blood pressure, and level of consciousness on arrival and every 30 minutes for duration of test.   |
| ☑  | Physician communication order  Medication Instructions: Clonidine dose = 5 mcg / kg, maximum 100 mcg (0.1 mg). Tablets can be cut into quarter or half, if needed.   |
| Se | elect one:   |
|    | cloNIDine 0.01 mg / mL suspension  ORAL, ONCE  Dose:   |
|    | cloNIDine HCI 0.1 mg Tablet ORAL, ONCE Dose:   |
| ☑  | Human growth hormone Unit collect, draw 30 minutes after cloNIDine dose.   |
| ☑  | Human growth hormone Unit collect, draw 60 minutes after cloNIDine dose.   |
| ☑  | Physician communication order  Medication Instructions: Arginine dose: 0.5 gm / kg, maximum dose 20 gm. Please enter the dose of arginine in 'gm' to facilitate prior authorization requirements   |
| V  | arginine 10 % injection INTRAVENOUS, ONCE, starting 1 hour after treatment start time. Give after drawing 60 minute sample for cloNIDine, give arginine over 30 minutes. Arginine 10 % is a hyperosmolar solution and may be infused with extreme caution via peripheral intravenous access if the patient does not have central venous access. In addition to visualizing, assessing and documenting the PIV site at the beginning and end of the infusion, the PIV site should also be monitored at the following intervals: Every 5 minutes x 3, then every 10 minutes until infusion is complete.  Dose: |



| Patient Name: _ |  |
|-----------------|--|
| Date of Birth:  |  |

Page 4 of 5

CMC84728-001NS Rev. 11/2020

# **Growth Hormone (Arginine / Clonidine) Stimulation Test**

### ORDERS TO BE COMPLETED FOR EACH THERAPY

| INTRA-PROCEDURE, CONTINUED   |
|--|
| Therapy appointment request Please select department for the therapy appointment request:                              |
| Growth hormone stimulation test is one time test. Patient needs to be fasting.   |
| Expires in 365 days  Dallas Special Procedures Plano Infusion Center Dallas Allergy Dallas Transplant Dallas Neurology |
| ✓ Human growth hormone Unit collect draw 30 minutes after arginine infusion complete.                                  |
| Human growth hormone     Unit collect draw 60 minutes after completion of arginine infusion.                           |
| ☑ Human growth hormone Unit collect draw 90 minutes after completion of arginine infusion.                             |
| ✓ Nursing communication If blood pressure < 20 mmHg from baseline, nurse may give 10 mL / kg NS bolus over 30 minutes. |
| ☑ Sodium chloride 0.9% for fluid bolus infusion  |
| 10 mL / kg, INTRAVENOUS, PRN, If blood pressure is < 20 mmHg from baseline, give 10 mL / kg NS over 30 minutes.  Dose: |
| EMERGENCY MEDICATIONS  |

## **☑** Nursing Communication

- 1. Hives or cutaneous reaction only no other system involvement PATIENT IS HAVING A DRUG REACTION:
  - a. Stop the infusion
  - b. Give diphenhydramine as ordered
  - c. Check vitals including blood pressure every 5 minutes until further orders from provider.
  - d. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one
  - e. Notify provider for further orders
- 2. Hives or cutaneous reaction plus one other system, i.e. abdominal cramping, vomiting, hypotension, altered mental status, respiratory distress, mouth / tongue swelling

# PATIENT IS HAVING ANAPHYLAXIS:

- a. Stop the infusion
- b. Call code do not wait to give epinephrine
- c. Give epinephrine as ordered
- d. Notify provider
- e. Check vitals including blood pressure every 5 minutes until the code team arrives.
- f. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one.
- g. Give diphenhydramine once as needed for hives
- h May repeat epinephrine every 5 minutes x 2 doses for persistent hypotension and respiratory distress with desaturation until code team
- i. May give albuterol as ordered for wheezing with oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation.



| Patient Name:  |  |
|----------------|--|
| Date of Birth: |  |

Page 5 of 5

Growth Hormone (Arginine / Clonidine)
Stimulation Test CMC84728-001NS Rev. 11/2020

# ORDERS TO BE COMPLETED FOR EACH THERAPY

| MEDGENCY | MEDICATIONS. | CONTINUED |
|----------|--------------|-----------|
| NERGENCI | MEDICA HUNG. | CONTINUED |

| EMERGENCY MEDICATIONS, CONTINUED  |  |                            |                            |
|---|--|----------------------------|----------------------------|
| Hypotension is defined as follows:  1 month to 1 year – systolic blood pressure (SBP) less than 7 year to 11 years – systolic blood pressure (SBP) less than 1 years to 17 years – systolic blood pressure (SPB) less than OR any age – systolic blood pressure (SPB) drop more than 8 Baseline systolic blood pressure x 0.7 = value below defined a | 70 + (2 x age in years<br>90<br>30% from baseline. | )                          |                            |
| □ EPINEPHrine Injection (AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaph distress with desaturation until the code team arrives, for 3 doses Use caution with PIV administration. This solution has a pH < 5, or a pH > Dose:   |  |                            | otension and respiratory   |
| ☐ Cardio / respiratory monitoring rationale for monitoring: high risk patient (please specify risk)  (Patient receiving infusion with potential infusion reactions); heart rate, respiratory rate, oxygen saturation  |  |                            |                            |
| Rationale for Monitoring: High risk patient (please specify risk) Parameters: heart rate, respiratory rate, oxygen saturation Alarm limits: preset at age specific limits   |  |                            |                            |
| ☐ diphenhydrAMINE injection   |  |                            |                            |
| 1 mg / kg, INTRAVENOUS, ONCE PRN,for hives or cutaneous reaction, f   | or 1 dose maximum o                                | dose = 50 mg per dose, 300 | 0 mg per day.              |
| ☐ Albuterol for aerosol   |  |                            |                            |
| 0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen satusaturation for 1 dose  Dose:   | urations stable while                              | waiting for code team, con | tinue to monitor oxygen    |
| POST - PROCEDURE  |  |                            |                            |
| ✓ Nursing communication  Flush PIV or IVAD with 10 - 20 mL 0.9% sodium chloride at the completion prior to de-accessing IVAD.   | on of the infusion. FI                             | ush IVAD with saline and h | neparin flush per protocol |
| ✓ Sodium chloride flush 0.9%  |  |                            |                            |
| INTRAVENOUS, at 0 - 25 mL / hr  Dose:   |  |                            |                            |
|   | (circle one):                                      |                            |                            |
| Signature of Provider   | Credentials  | Date                       | Time                       |
| Printed Name of Provider  |  |                            |                            |